载脂蛋白(a)抑制血管内皮细胞的体外管腔形成:对 Kringle V 和纤溶酶原激活系统作用的鉴定。

Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system.

机构信息

Department of Biochemistry, Queen's University, Kingston, Ontario, Canada.

出版信息

PLoS One. 2013;8(1):e52287. doi: 10.1371/journal.pone.0052287. Epub 2013 Jan 11.

Abstract

Elevated plasma concentrations of lipoprotein(a) are associated with increased risk for atherothrombotic diseases. Apolipoprotein(a), the unique glycoprotein component of lipoprotein(a), is characterized by the presence of multiple kringle domains, and shares a high degree of sequence homology with the serine protease zymogen plasminogen. It has been shown that angiostatin, a proteolytic fragment of plasminogen containing kringles 1-4, can effectively inhibit angiogenesis. Moreover, proteolytic fragments of plasminogen containing kringle 5 are even more potent inhibitors of angiogenesis than angiostatin. Despite its strong similarity with plasminogen, the role of apolipoprotein(a) in angiogenesis remains controversial, with both pro- and anti-angiogenic effects reported. In the current study, we evaluated the ability of apolipoprotein(a) to inhibit VEGF- and angiopoietin-induced tube formation in human umbilical cord endothelial cells. A 17 kringle-containing form of recombinant apo(a) (17K), corresponding to a well-characterized, physiologically-relevant form of the molecule, effectively inhibited tube formation induced by either VEGF or angiopoietin-1. Using additional recombinant apolipoprotein(a) (r-apo(a)) variants, we demonstrated that this effect was dependent on the presence of an intact lysine-binding site in kringle V domain of apo(a), but not on the presence of the functional lysine-binding site in apo(a) kringle IV type 10; sequences within in the amino-terminal half of the molecule were also not required for the inhibitory effects of apo(a). We also showed that the apo(a)-mediated inhibition tube formation could be reversed, in part by the addition of plasmin or urokinase plasminogen activator, or by removal of plasminogen from the system. Further, we demonstrated that apo(a) treated with glycosidases to remove sialic acid was significantly less effective in inhibiting tube formation. This is the first report of a functional role for the glycosylation of apo(a) although the mechanisms underlying this observation remain to be determined in the context of angiogenesis.

摘要

脂蛋白(a)的血浆浓度升高与动脉血栓性疾病的风险增加有关。载脂蛋白(a)是脂蛋白(a)的独特糖蛋白成分,其特征是存在多个kringle 结构域,并且与丝氨酸蛋白酶原纤溶酶具有高度的序列同源性。已经表明,血管抑素,即含有kringle 1-4 的纤溶酶原的蛋白水解片段,可有效抑制血管生成。此外,含有kringle 5 的纤溶酶原的蛋白水解片段比血管抑素更能抑制血管生成。尽管与纤溶酶具有很强的相似性,但载脂蛋白(a)在血管生成中的作用仍存在争议,既有促血管生成作用,也有抗血管生成作用。在本研究中,我们评估了载脂蛋白(a)抑制人脐静脉内皮细胞中 VEGF 和血管生成素诱导的管形成的能力。一种含有 17kringle 的重组 apo(a)(17K)形式,对应于分子的一种特征明显的、生理相关的形式,可有效抑制 VEGF 或血管生成素-1 诱导的管形成。使用其他重组载脂蛋白(a)(r-apo(a))变体,我们证明这种作用依赖于 apo(a)kringle V 结构域中完整赖氨酸结合位点的存在,但不依赖于 apo(a)kringle IV 型 10 中的功能性赖氨酸结合位点;分子氨基端的序列也不需要 apo(a)的抑制作用。我们还表明,apo(a)介导的管形成抑制作用可部分通过添加纤溶酶或尿激酶纤溶酶原激活剂,或通过从系统中去除纤溶酶原来逆转。此外,我们证明用糖苷酶处理以去除唾液酸的 apo(a)在抑制管形成方面的效果明显降低。这是首次报道载脂蛋白(a)的糖基化具有功能作用,尽管在血管生成的背景下,这种观察结果的机制仍有待确定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcea/3543409/ee5c14bb185e/pone.0052287.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索